Minute Insight: Exai, Freenome Announce Major Financings To Advance Early Cancer Detection
Executive Summary
Freenome, developer of a blood test for early detection of colorectal cancer, announced a $300m series D funding. Exai Bio secured a $67.5m series A financing to accelerate development of its non-invasive, RNA-based liquid biopsy platform for early cancer detection.